Incidence rare: Changes in lenses of eyes - usually asymptomatic; galactorrhea (unusual secretion of milk) - in females; hypothyroidism (loss of appetite; weight gain; dry, puffy skin; tiredness); hypotension (low blood pressure); menstrual changes; neuroleptic malignant syndrome (NMS) (difficult or unusually fast breathing; fast heartbeat or irregular pulse; high fever; high or low [irregular] blood pressure; increased sweating; loss of bladder control; severe muscle stiffness; seizures; unusual pale skin; unusual tiredness or weakness); seizures; tachycardia (fast, pounding, or irregular heartbeat; fainting).
Note: Changes in the lenses of the eyes have been observed in patients during long-term Quetiapine therapy and cataracts have developed in dogs during chronic Quetiapine dosing. Regular ophthalmologic examinations are recommended during Quetiapine therapy.
Those indicating need for medical attention only if continue or are bothersome: Incidence more frequent: Constipation; dizziness; drowsiness; dry mouth; dyspepsia (indigestion); increased weight.
Note: Dyspepsia and increased weight are dose-related. In pooled data from 3- to 6-week trials, 23% of patients receiving Quetiapine and 6% of patients receiving placebo gained ≥ 7% of their baseline body weight.
Incidence less frequent: Abdominal pain; abnormal vision; anorexia (decrease in appetite); asthenia (decreased strength and energy); headache; hypertonia (increased muscle tone); increased sweating; palpitation (feeling of fast or irregular heartbeat); pharyngitis (sore throat); rhinitis (stuffy or runny nose).
Note: Abdominal pain is dose-related.
View ADR Monitoring Form